Subject Expert Committee gives nod to Covaxin for Phase 2, 3 trials on children aged 2 to 18 years
Subject Expert Committee gives nod to Covaxin for Phase 2, 3 trials on children aged 2 to 18 years
newKerala.com
0 shares
1 views
You might like
Related news coverage
NA Proactive news snapshot: TechX Technologies, Binovi Technologies, Versus Systems, Organic Garage, NEXE Innovations UPDATE …
Proactive Investors
TechX Technologies Inc (CSE:TECX) has entered into a debt settlement agreement pursuant to which the company has agreed to issue..
-
NA Proactive news snapshot: PyroGenesis Canada, RedHill Biopharma, Australis Capital, Energy Fuels, Marvel Discovery UPDATE …
Proactive Investors
-
NA Proactive news snapshot: Safe-T Group, Altiplano Metals, Esports Entertainment Group, FPX Nickel UPDATE …
Proactive Investors
-
NA Proactive news snapshot: Else Nutrition, Bam Bam Resources, Plurilock Security, Valeo Pharma, Benchmark Metals …
Proactive Investors
-
Covaxin gets nod for phase II/III trials on 2 to 18-year-olds
IndiaTimes
Advertisement
More coverage
Bharat Biotech`s Covaxin gets approval for phase 2/3 trials on 2-18 year-olds
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated..
Zee News
NA Proactive news snapshot: Mountain Valley MD, Zynerba Pharmaceuticals, TRACON Pharmaceuticals, Kainantu Resources, Ready Set Gold UPDATE …
Mountain Valley MD Holdings Inc (CSE:MVMD) (FRA:20MP) (OTCQB:MVMDF) announced that it has filed a novel cancer adjuvant patent and..
Proactive Investors